Dr. Kumar’s Take:
This study gives me updated insights into a controversial class of cholesterol-targeting drugs, CETP inhibitors. CETP stands for Cholesteryl Ester Transfer Protein, a glycoprotein made by the liver that moves cholesteryl esters and triglycerides between lipoprotein particles. Blocking CETP raises cholesterol carried in HDL and lowers cholesterol in ApoB-containing particles like LDL and VLDL, but whether that translates into fewer cardiovascular events has been a long-running question.
This meta-analysis found that CETP inhibitors reduced cardiovascular death and myocardial infarction, with the heart attack benefit attributed primarily to anacetrapib. No other outcome improved. That is a narrow win, not a class-wide victory:
- ✔ Anacetrapib drove the reduction in myocardial infarction.
- ⚠ Torcetrapib was excluded from this analysis entirely.
- 🆕 Obicetrapib is the newest agent to reach late-stage development, and its story is still being written.
That said, this doesn’t mean everyone needs these drugs. If you’re already low-risk, they likely won’t make much difference. For people with high LDL and high cardiovascular risk, especially those who can’t tolerate statins, this class may eventually become another tool in the toolbox. I would not change anyone’s regimen on the strength of this analysis alone.
Brief Summary:
This systematic review and meta-analysis pooled nine randomized controlled trials comparing CETP inhibitors against placebo to evaluate whether these drugs reduce cardiovascular events. The drugs raise HDL-C and, for most of them, lower LDL-C and ApoB, but their clinical benefit has been unclear. The pooled data showed reductions in cardiovascular-related mortality and myocardial infarction. No other outcome, including all-cause mortality and stroke, was reduced.
Key Takeaways:
✔ CETP inhibitors reduced cardiovascular-related mortality (RR = 0.89; 95% CI: 0.81 to 0.98; p = 0.02; I² = 0%).
✔ They reduced myocardial infarction (RR = 0.92; 95% CI: 0.86 to 0.98; p = 0.01; I² = 0%), primarily attributed to anacetrapib.
✔ No reduction in any other outcome, including all-cause mortality, stroke, revascularization, and hospitalization for acute coronary syndrome.
✔ Heterogeneity was zero for both positive findings, meaning the trials agreed with each other.
Study Design:
The authors searched PubMed, Embase, MEDLINE, and the Cochrane Library from database inception in 2003 through 27 October 2023, following PRISMA guidelines. Eligible studies were randomized controlled trials comparing a CETP inhibitor to placebo in adults aged 18 and over, enrolling at least 100 participants, with at least 6 months of follow-up. Trials of torcetrapib were excluded, as were reviews, editorials, and letters. Two reviewers independently screened and extracted data, with a third resolving disagreements. Risk of bias was assessed with RoB 2.0, and pooled effects were calculated in Review Manager 5.4 using a random effects model. Nine trials met criteria. Primary outcomes were major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality. Secondary outcomes were stroke, revascularization, hospitalization for acute coronary syndrome, and myocardial infarction. Subgroup analyses were run by drug.
Results:
✔ Cardiovascular Mortality:
- Relative Risk (RR): 0.89
- 95% Confidence Interval: 0.81 to 0.98
- p = 0.02, I² = 0%
- Interpretation: A statistically significant reduction, consistent across the included trials.
✔ Myocardial Infarction (Heart Attack):
- RR: 0.92
- 95% Confidence Interval: 0.86 to 0.98
- p = 0.01, I² = 0%
- Interpretation: A statistically significant reduction, attributed primarily to anacetrapib.
By Drug:
The search targeted anacetrapib (MK-0859), evacetrapib (LY2484595), obicetrapib (TA-8995), and dalcetrapib (JTT-705). Torcetrapib trials were excluded by design. Within the pooled analysis, the myocardial infarction benefit was primarily attributed to anacetrapib.
❌ No reduction was found for:
- Major adverse cardiovascular events
- All-cause mortality
- Stroke
- Hospitalization due to acute coronary syndrome
- Need for revascularization
How CETP Inhibitors Work:
CETP is a glycoprotein synthesized by the liver. Its shape lets it bind both cholesteryl esters and triglycerides, and it shuttles these molecules between plasma lipoprotein particles. The net effect of normal CETP activity is a transfer of cholesteryl esters out of HDL and into VLDL and LDL, and a transfer of triglycerides out of VLDL and chylomicrons into LDL and HDL. Inhibiting CETP reduces these exchanges, so cholesterol concentrations rise in HDL and fall in ApoB-containing particles.
The idea came partly from genetics. Mutations in the CETP gene were found to raise HDL-C and lower LDL-C in multiple families, and several single-nucleotide polymorphisms in the gene were linked to lower CETP activity and lower ASCVD risk. Species differences point the same way: rabbits, which have CETP, develop atherosclerosis on a high-cholesterol diet, while rodents, which lack it, are naturally resistant.
Raising HDL-C on its own has not proven to be enough. Trials of niacin and fibrates, which also raise HDL-C, did not support that hypothesis. In the REVEAL trial of anacetrapib, the reduction in major adverse cardiovascular events correlated directly with reductions in non-HDL-C, not with the HDL-C increase. That distinction matters for interpreting this whole drug class.
Related Studies and Research
Ezetimibe and Heart Disease: A Review: Examines how ezetimibe lowers LDL cholesterol and its effect on cardiovascular outcomes.
Fibrates and Cardiovascular Risk Reduction: Explores the role of fibrates in lipid management and their effect on heart disease risk.
Red Yeast Rice and Metabolic Syndrome: Investigates how red yeast rice affects lipid levels and metabolic markers in people with metabolic syndrome.
Plant Sterols, Cholesterol, and Heart Health: Reviews how plant sterols impact cholesterol levels and their potential role in heart disease prevention.
Small, Dense LDL and Atherosclerosis: Investigates how particle size influences LDL’s atherogenicity and risk.
ApoB vs. LDL Cholesterol: Which is the Better Risk Marker?: Compares different lipid markers for predicting heart disease risk.
Frequently Asked Questions
Are CETP inhibitors a replacement for statins?
No. Statins remain the foundation of lipid-lowering therapy, alongside ezetimibe, PCSK9 inhibitors, and bempedoic acid. CETP inhibitors are being studied as an addition to that foundation, not a substitute for it.
Do CETP inhibitors help everyone?
The pooled benefit was limited to cardiovascular mortality and myocardial infarction. Nothing here supports giving these drugs broadly. They make the most sense to study in people whose ApoB and LDL-C stay high on existing therapy.
Why didn’t they reduce strokes or overall deaths?
The analysis found no reduction in those outcomes. Total mortality includes many causes unrelated to atherosclerosis, and stroke has mechanisms beyond cholesterol, so a drug acting on lipoproteins would not be expected to move either as reliably as it moves myocardial infarction.
Which CETP inhibitor performed best?
The reduction in myocardial infarction was primarily attributed to anacetrapib. Obicetrapib is the most recent agent to reach late-stage clinical development.
Conclusion
CETP inhibitors are not miracle drugs. This meta-analysis reports, for the first time, that the class is associated with reduced cardiovascular mortality and reduced myocardial infarction, and with nothing else. The authors’ own framing is worth holding onto: earlier trials of this class failed to reduce atherosclerotic cardiovascular events, and a meaningful share of cardiovascular events cannot be prevented by lowering LDL-C alone.
The simple version of the HDL hypothesis, that raising HDL-C prevents disease, does not hold up. The signal that survives is tied to lowering ApoB-containing lipoproteins. For now, a focus on overall risk reduction, including lifestyle, blood pressure, inflammation, and metabolic health, remains the best strategy.
